天然产物研究与开发 ›› 2015, Vol. 27 ›› Issue (Suppl): 197-204.doi: 10.16333/j.1001-6880.2015.S.045

• 综述 • 上一篇    下一篇

GPR119:治疗二型糖尿病和肥胖的新靶点

孙丰慧,王频佳,程曦,林琳,代敏*   

  1. 成都医学院,成都 610500
  • 出版日期:2015-12-01 发布日期:2016-01-12

GPR119:A Novel Therapeutic Receptor for Type 2 Diabetes and Obesity

SUN Feng-hui,WANG Pin-jia,CHENG Xi,LIN Lin,DAI Min*   

  1. Chengdu Medical College,Chengdu 610500,China
  • Online:2015-12-01 Published:2016-01-12

摘要: 二型糖尿病(T2D)是当前严重威胁人类健康的一类重要疾病。多年来的流行病学分析显示,肥胖与T2D有着密切的联系。GPR119是近年来发现的抗T2D和肥胖的新靶点。在体外及动物模型中,GPR119具有调节葡萄糖代谢、影响食物摄取、降低体重的功能。近年来国外对其分子机理及激动剂的研究日益增多,本文对相关研究进展做一综述。

关键词: GPR119, 激动剂, G蛋白偶联受体, 二型糖尿病, 肥胖

Abstract: Type 2 diabetes (T2D) is one of the leading causes of morbidity and mortality all over the world.Epidemiologic studies have demonstrated that the patients with obesity have increased risk of diabetes.A novel G protein coupled receptor(GPCR),GPR119,was identified and has emerged as arguably one of the most exciting targets for the treatment of T2D and obesity. In vitro and in vivo, GPR119 play a key role in modulating glucose homeostasis,food intake,weight loss.This review summarizes the research leading to the identification of GPR119 as a potential drug target for T2D and related metabolic disorders.In addition,an overview of the recent progress made in the discovery of orally active GPR119 agonists is provided.

Key words: GPR119, agonist, G protein-coupled receptor, Type 2 diabetes, Obesity

中图分类号: 

Q73 R587.1